Israeli pharmaceutical company, Teva Pharmaceutical Industries, is collaborating with Intel Corp to develop a smartwatch to track the progression of disease in patients with Huntington’s, a genetic condition that causes fatal degenerative disorder.
Currently there’s no cure for the condition that affects movement and leads to cognitive decline but, through their collaboration, Teva and Intel are hoping to use technology to help progress research for future treatments. Patients typically succumb to the disease within 15-25 years of diagnosis.
The two companies will deploy the technology as part of an ongoing mid-stage Huntington’s study. The platform will monitor and analyse key symptoms that impact daily living to better understand disease progression and improve treatment evaluation.
Patients will use a smartphone and wear a smartwatch equipped with sensing technology that will continuously measure functioning and movement. The collected data will sync with a smartphone app then wirelessly stream to an Intel cloud-cased platform which will interpret the data and score the information in real time to assess motor symptom severity.
This is not the first time that the pharmaceutical giant has partnered with a technology company. In 2015, Teva announced a partnership with IBM’s Watson Health to develop global eHealth solutions using the Watson Health Cloud to benefit patients and healthcare providers across geographies.
Teva is the first Foundational Life Sciences Partner for the Watson Health Cloud and aims to use it to target complex and chronic conditions such as asthma, pain, migraine and neurodegenerative diseases.
In addition, a joint Teva-IBM Research team will deploy big data and machine learning technology to create disease models and advanced therapeutic solutions.